Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blaise

Showing results (181-190 of 284) with videos related to

Pageof 29
Sort By:
Transfusion|March 27, 2004
Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb levelV Ivanov, C Faucher, M Mohty, et al.
British Journal of Haematology|September 6, 2000
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)J Y Cahn, M Labopin, J Sierra, et al.
Leukemia & Lymphoma|January 1, 1996
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's diseaseJ Fleury, M Legros, P Colombat, et al.
Hematology (Amsterdam, Netherlands)|September 24, 2002
Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantationM Mohty, B Gaugler, C Faucher, et al.
Bone Marrow Transplantation|October 3, 2020
Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMTJ Loke, M Labopin, C Craddock, et al.
Bone Marrow Transplantation|November 5, 2003
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)F Millot, H Esperou, P Bordigoni, et al.
British Journal of Haematology|November 25, 2000
Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow TransplantationP Guardiola, M Kuentz, F Garban, et al.
Leukemia|June 9, 1999
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patientsR Bouabdallah, A M Stoppa, J F Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphomaA M Stoppa, R Bouabdallah, C Chabannon, et al.
Bone Marrow Transplantation|February 8, 2018
Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Pageof 29

Showing results (181-190 of 284) with videos related to

Sort By:
Pageof 29
Transfusion|March 27, 2004
Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb levelV Ivanov, C Faucher, M Mohty, et al.
British Journal of Haematology|September 6, 2000
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)J Y Cahn, M Labopin, J Sierra, et al.
Leukemia & Lymphoma|January 1, 1996
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's diseaseJ Fleury, M Legros, P Colombat, et al.
Hematology (Amsterdam, Netherlands)|September 24, 2002
Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantationM Mohty, B Gaugler, C Faucher, et al.
Bone Marrow Transplantation|October 3, 2020
Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMTJ Loke, M Labopin, C Craddock, et al.
Bone Marrow Transplantation|November 5, 2003
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)F Millot, H Esperou, P Bordigoni, et al.
British Journal of Haematology|November 25, 2000
Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow TransplantationP Guardiola, M Kuentz, F Garban, et al.
Leukemia|June 9, 1999
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patientsR Bouabdallah, A M Stoppa, J F Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphomaA M Stoppa, R Bouabdallah, C Chabannon, et al.
Bone Marrow Transplantation|February 8, 2018
Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Pageof 29